Xentria Announces the Initiation of a Clinical Trial for XTMAB-16 for the Treatment of Sarcoidosis

CHICAGO--(BUSINESS WIRE) June 22, 2021--Xentria Inc., a biopharmaceutical company focused on developing novel biologics to address unmet clinical needs, today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials